Academic Medical Center, Meibergdreef
Atherogenic inflammation may be target for therapeutic development of mycophenolate mofetil
Published in Medical Device Law Weekly, April 9th, 2006
According to the review from The Netherlands, "Atherosclerosis is characterized by a persistent, low-grade inflammatory state in which immune cell activation is inseparably linked to plaque formation and destabilization. The T-lymphocyte in particular has emerged as a pivotal player throughout the course of atherogenesis."
"As a consequence," explained S.I. van Leuven and colleagues at the Academic Medical Center in Meibergdreef, "the concept that immune modulation is a suitable target for cardiovascular...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Law Weekly
More Articles from Medical Device Law Weekly
- Dana-Farber Cancer Institute, Boston
Ovarian cancer patients treated by gynecologic oncologists had better outcomes - FEI Company
FEI and Sidec tackle validation of drug targets - Henry Ford Hospital, Detroit
Hospital resources are consumed in treating complications associated with PCI - King Pharmaceuticals, Inc.
King, Aventis, Cobalt agree to dismiss patent litigation regarding ACE inhibitor Altace - Luminex Corporation
Luminex signs licensing agreement with MIT for development of microRNA assays and products - Medical Devices
Merit Medical introduces stiffened dilator mini access kit, S-MAK - More from this issue of Medical Device Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
